Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

(2022) Alison Tarke et al.   CELL

T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant

(2022) Seong Jin Choi et al.   Cellular & Molecular Immunology

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

(2022) Emma K. Accorsi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2022) Elisabetta Cameroni et al.   NATURE

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

(2022) Henning Gruell et al.   NATURE MEDICINE

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

(2022) Yu Gao et al.   NATURE MEDICINE

Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England

(2022) Nick Andrews et al.   NATURE MEDICINE

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

(2022) Annika Rössler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

(2021) Wanwisa Dejnirattisai et al.   LANCET

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE